Ablynx looks to partnering as nanobody for RA meets endpoint
This article was originally published in Scrip
Executive Summary
Ablynx 's anti-IL-6R nanobody, ALX-0061, has met the efficacy endpoint of a significant improvement in key indicators of disease activity at the 12-week interim analysis of the Phase I/II study in patients with moderate to severe active rheumatoid arthritis (RA) on a stable background of methotrexate.